secwatch.observer — SEC 8-K summary
======================================

Issuer:     REVVITY, INC. (RVTY)
CIK:        0000031791
Form:       8-K
Filed at:   2026-05-05T23:59:59+00:00
Accession:  0000031791-26-000016
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Revvity Q1 adj EPS $1.06 beats $1.01 YoY; revenue $711M +7%; plans China IDX divestiture
--------------------------------------------------------------------------------

- Q1 GAAP EPS $0.37 vs $0.35 YoY; adjusted EPS $1.06 vs $1.01; revenue $711M (+7% YoY).
- Pro forma (ex-China IDX) revenue $687M, adj EPS $1.04 vs $0.95 YoY.
- Signed LOI to sell China Immunodiagnostics business for up to $200M; expects close by 2027.
- China IDX represented ~6% of FY2025 total revenue; definitive agreement expected Q2 2026.
- Full-year 2026 guidance updated on pro forma basis; management to discuss on call.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/31791/000003179126000016/0000031791-26-000016-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/31791/000003179126000016/pki-20260505.htm
  HTML page:      https://secwatch.observer/filing/0000031791-26-000016

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer